Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...

Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...

Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...

Department of Ophthalmology, Okayama University Medical School, Okayama City, Japan Correspondence to: Toshihiko Matsuo, MD, Department of Ophthalmology, Okayama University Medical School, 2-5-1 ...

Correspondence to Felipe A Medeiros, Visual Performance Laboratory, Duke Eye Center and Department of Ophthalmology, Duke University, 2310 Erwin Rd, Durham, NC 27710, USA; felipe.medeiros{at}duke.edu ...

Background: Patients with iridocyclitis are at heightened risk for immune-mediated diseases. The genetic underpinnings of iridocyclitis are intricate, necessitating an integrated approach to unravel ...

Heterochromia is when someone has two differently colored eyes or patches of color in one eye. It can be present from birth (congenital) or develop later in life due to another condition or injury.

Objectives To compare efficacy and safety of various doses of tofacitinib, an oral Janus kinase inhibitor, with placebo in patients with active ankylosing spondylitis (AS, radiographic axial ...